Natasha Giordano, Dipexium Pharmaceuticals, Inc.'s President and CEO and a director of the company, recently acquired 1,086 shares of the company. The buys took place at $0.00 per share (and therefore, likely the result of option or restricted share grants), on April 19, 2017. Giordano now owns 1,086 shares of the company. Giordano operates out of Houston, TX. Some additional info was provided as follows:
Received in exchange for 1,380 shares of common stock of PLx Opco Inc. (formerly PLx Pharma Inc.) in connection with the merger (the "Merger") of PLx Opco Inc. with a wholly owned subsidiary of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.).
Received in connection with the Merger in exchange for an employee stock option to buy 275,000 shares of PLx Opco I
nc. common stock for $9.80 per share.
The option is exercisable as to 108,290 shares as of the date hereof, and will become exercisable as to an additional 54,145 shares on each of January 1, 2018 and (subject to continued employment through such date) January 1, 2019.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Dipexium Pharmaceuticals, Inc. makes a similar move, sign up!
Other recent filings from the company include the following:
General statement of acquisition of beneficial ownership - Nov. 20, 2017
Dipexium Pharmaceuticals, Inc. Just Filed Its Quarterly Report: Loss per share Basic... - Nov. 9, 2017
Departure of Directors or Certain - Oct. 27, 2017